E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
unresectable hepatocellular carcinoma (HCC) |
Carcinoma hepatocelular irresecable |
|
E.1.1.1 | Medical condition in easily understood language |
liver cancer that cannot be removed by surgery |
Cáncer de hígado en el que la cirugía no está indicada. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10019828 |
E.1.2 | Term | Hepatocellular carcinoma non-resectable |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of durvalumab plus tremelimumab compared with sorafenib. |
Evaluar la eficacia del tratamiento combinado de durvalumab tremelimumab en comparación con sorafenib. |
|
E.2.2 | Secondary objectives of the trial |
-To assess the efficacy of durvalumab monotherapy and durvalumab plus tremelimumab combination therapy compared with sorafenib -To assess the efficacy of all immunotherapy arms compared with sorafenib by PD-L1 expression -To assess disease-related symptoms and health-related quality of life (HRQoL) in patients treated with all immunotherapy arms compared with sorafenib - To evaluate the population PK and pharmacodynamics of all immunotherapy arms - To investigate the immunogenicity of all immunotherapy arms |
- Evaluar la eficacia del tratamiento combinado de durvalumab y tremelimumab en comparación con sorafenib. - Evaluar la eficacia de todos los grupos de inmunoterapia en comparación con sorafenib según la expresión de PD-L1. - Evaluar los síntomas relacionados con la enfermedad y la calidad de vida relacionada con la salud (HRQoL) en pacientes tratados con todos los grupos de inmunoterapia en comparación con sorafenib. - Evaluar la farmacocinética poblacional y la farmacodinamia de todos los grupos de inmunoterapia. - Investigar la inmunogenicidad de todos los grupos de inmunoterapia. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- HCC (unresectable hepatocellular carcinoma) histopathological diagnosis confirmation based on tumor tissue - No prior systemic therapy for HCC - Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C - Child-Pugh Score class A - ECOG performance status of 0 or 1 at enrollment |
- Carcinoma hepatocelular irresecable (HCC) de confirmación diagnóstica histopatológica basada en tejido tumoral. - No haber recibido terapia sistémica para HCC. - Estadio B según la clasificación BCLC (Barcelona Clinic Liver Cancer) no aptos para recibir tratamiento locorregional o en estadio C. - Clase A según la clasificación de Chil-Pugh. - Estado funcional del ECOG de 0 a 1 en la inclusión. |
|
E.4 | Principal exclusion criteria |
- Hepatic encephalopathy within past 12 months or requirement for medication to prevent or control encephalopathy - Ascites that requires ongoing paracentesis to control symptoms (within 6 weeks prior to the first scheduled dose) - Main portal vein thrombosis - Active or prior documented GI variceal bleed or history of upper GI bleeding, ulcers or esophageal varices with bleeding within 12 months - HBV and HCV co-infection |
- Encefalopatía hepática en los últimos 12 meses o medicamentos requeridos para prevenir o controlar la encefalopatía - Ascitis que requiere paracentesis continua para controlar los síntomas (dentro de las 6 semanas anteriores a la primera dosis programada) - Trombosis de la vena porta principal - Sangrado váricoso gastrointestinal activo o previamente referenciado o antecedentes de hemorragia gastrointestinal superior, úlceras o varices esofágicas con sangrado dentro de los 12 meses - Coinfección por VHB y VHC |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall survival (OS) is defined as the time from the date of randomization until death due to any cause. |
La Supervivencia Global (SG) es definida en el momento desde la fecha de la aleatorización hasta la muerte debida a cualquier causa. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Patient level: Assessments for survival will be made every 4 weeks during treatment period and every 2 months following treatment discontinuation which will continue until the end of the study unless the patient has expressly withdrawn their consent to survival follow-up. In addition, all patients will be contacted in the week following data cutoff to confirm survival status. |
Nivel del paciente: Las evaluaciones de supervivencia se harán cada 4 semanas durante el período de tratamiento y cada 2 meses después de la interrupción del tratamiento que continuará hasta el final del estudio a menos que el paciente haya retirado expresamente su consentimiento para el seguimiento de la supervivencia. Además, todos los pacientes serán contactados en la semana siguiente al corte de datos para confirmar el estado de supervivencia. |
|
E.5.2 | Secondary end point(s) |
Other secondary efficacy endpoints include: OS (Overall survival), Time to progression (TTP), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and duration of response (DoR) |
Otras variables secundarias de eficacia incluyen: OS (supervivencia global), Tiempo hasta la progresión (TTP), Supervivencia libre de progresión (PFS), Tasa de respuesta objetiva (ORR), Tasa de control de la enfermedad (DCR), y Duración de la respuesta (DoR) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
TTP, PFS, ORR, DoR, DCR - Patient level: Efficacy for all patients will be assessed by objective tumor assessments every 8 weeks (±1 week) for the first 48 weeks (relative to the date of randomization; then every 12 weeks (±1 week) thereafter until confirmed PD as defined by RECIST 1.1 or discontinuation from study participation.
OS18 and OS24 - Patient level: Assessments for survival will be made every 4 weeks during treatment period and every 2 months following treatment discontinuation which will continue until the end of the study unless the patient has expressly withdrawn their consent to survival follow-up. In addition, all patients will be contacted in the week following data cutoff to confirm survival status. |
TTP, PFS, ORR, DoR, DCR-Nivel del pcnte: La eficacia para todos los pcntes se evaluará mediante evaluaciones objetivas del tumor cada 8 emanas (±1 semana) durante las primeras 48 semanas (con relación a la fecha de inclusión); después cada 12semanas (±1 semana) hasta que se confirme la PD como se define en RECIST 1.1 o la interrupción de la participación en el estudio. OS18 y OS24-Nivel del pcnte: Las evaluaciones de superv se realizarán cada 4 semanas durante el período de tto y cada 2 meses después de la suspensión del tto, que continuará hasta el final del estudio a menos que el pcnte haya retirado expresamente su consentimiento para el seguimiento de la superv. Además, todos los pcntes serán contactados en la semana siguiente al corte de datos para confirmar el estado de superv. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability Healthcare resource utilization Quality of life |
Tolerailidad Utilización de los recursos sanitarios Calidad de vida |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 39 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Brazil |
Canada |
China |
France |
Germany |
Hong Kong |
India |
Italy |
Japan |
Korea, Republic of |
Russian Federation |
Spain |
Taiwan |
Thailand |
Ukraine |
United States |
Vietnam |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patients’ treatment discontinuation. |
El final del estudio se define como "la última visita del último sujeto que participe en el estudio" |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |